Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial
Martin J. van den Bent(Erasmus MC Cancer Institute), Ahmed Idbaïh(Centre National de la Recherche Scientifique), Michael Weller(University Hospital of Zurich), Pim J. French(Erasmus MC Cancer Institute), Iris de Heer(Erasmus MC Cancer Institute), Filip De Vos(University Medical Center Utrecht), Martin Klein(Amsterdam University Medical Centers), Corneel Coens(European Organisation for Research and Treatment of Cancer), Thierry Gorlia(European Organisation for Research and Treatment of Cancer), Antje Wick(Heidelberg University), Tina Verschuere(KU Leuven), Marion Smits(Erasmus MC), Paul Mulholland(University College London Hospitals NHS Foundation Trust), Martin Taphoorn(Leiden University Medical Center), Johan M. Kros(Erasmus MC), Olivier Chinot(Aix-Marseille Université), Joanne Lewis(Freeman Hospital), Paul M. Clément(Universitair Ziekenhuis Leuven), Vassilis Golfinopoulos(Champalimaud Foundation), Jaap C. Reijneveld(Amsterdam UMC Location University of Amsterdam)
Cited by 131
Related Papers
Recommended implementation of arterial spin‐labeled perfusion MRI for clinical applications: A consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia
|Magnetic Resonance in Medicine|2014|2.2k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Medulloblastoma Comprises Four Distinct Molecular Variants
|Journal of Clinical Oncology|2010|1.4k